Literature DB >> 6357912

Effect of insulin replacement on intermediary metabolism in diabetes secondary to pancreatectomy.

S Del Prato, A Tiengo, U Baccaglini, C Tremolada, E Duner, M C Marescotti, A Avogaro, I Valverde, R Nosadini, R Assan.   

Abstract

Patients with diabetes due to pancreatectomy have metabolic features different from Type 1 (insulin-dependent) diabetes after insulin withdrawal. Whether or not glucagon by itself or combined glucagon-insulin absence are responsible for this metabolic behaviour is unknown. This study was carried out to evaluate the ability of insulin replacement to abolish differences between patients with Type 1 diabetes and patients with diabetes due to pancreatectomy. We studied the diurnal patterns of intermediary metabolites, free insulin, and glucagon using the Biostator (glucose-controlled insulin infusion system) and intensive subcutaneous insulin therapy in five patients after total pancreatectomy, five after partial pancreatectomy and seven patients with Type 1 diabetes. All were studied for 24 h after an overnight period of normoglycaemia. Insulin requirement was lower in the patients with total pancreatectomy than in patients with partial pancreatectomy or Type 1 diabetes during both types of insulin treatment (p less than 0.05). Blood glucose and free insulin were similar in all the groups in both conditions. Immunoreactive glucagon was higher in the patients with diabetes secondary to pancreatectomy than in Type 1 diabetic patients. However, glucagon levels did not increase after arginine infusion in the patients with total pancreatectomy, and column chromatography of blood samples from two totally pancreatectomized patients showed no significant levels of immunoreactive pancreatic glucagon. Non-esterified fatty acids and ketone bodies were similar during Biostator and intensive subcutaneous insulin therapy. By contrast, gluconeogenic precursors (lactate, pyruvate, alanine and glycerol) were higher in patients with total pancreatectomy than in patients with partial pancreatectomy and Type 1 diabetes.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6357912     DOI: 10.1007/bf00279939

Source DB:  PubMed          Journal:  Diabetologia        ISSN: 0012-186X            Impact factor:   10.122


  45 in total

1.  Enzymatic microdetermination of serum free fatty acids.

Authors:  S Shimizu; K Inoue; Y Tani; H Yamada
Journal:  Anal Biochem       Date:  1979-10-01       Impact factor: 3.365

2.  A kinetic spectrophotometric assay for rapid determination of acetoacetate in blood.

Authors:  C P Price; B Llyod; G M Alberti
Journal:  Clin Chem       Date:  1977-10       Impact factor: 8.327

3.  A simple method for the determination of serum free insulin levels in insulin-treated patients.

Authors:  S Nakagawa; H Nakayama; T Sasaki; K Yoshino; Y Y Yu
Journal:  Diabetes       Date:  1973-08       Impact factor: 9.461

4.  A temperature conversion nomogram for glycosylated hemoglobin analysis.

Authors:  W D Hankins; L Holladay
Journal:  Clin Chim Acta       Date:  1980-06-10       Impact factor: 3.786

5.  Hyperglucagonemia and blood glucose regulation in normal, obese and diabetic subjects.

Authors:  R S Sherwin; M Fisher; R Hendler; P Felig
Journal:  N Engl J Med       Date:  1976-02-26       Impact factor: 91.245

6.  Clinical and hormonal aspects of pancreatic diabetes.

Authors:  S Bank; I N Marks; A I Vinik
Journal:  Am J Gastroenterol       Date:  1975-07       Impact factor: 10.864

7.  Effects of glucagon on lipolysis and ketogenesis in normal and diabetic men.

Authors:  J E Liljenquist; J D Bomboy; S B Lewis; B C Sinclair-Smith; P W Felts; W W Lacy; O B Crofford; G W Liddle
Journal:  J Clin Invest       Date:  1974-01       Impact factor: 14.808

8.  Glucagon and N6,O2'-dibutyryl adenosine 3':5'-monophosphate inhibition of lipogenesis and phosphofructokinase activity of hepatocytes from meal-fed rats.

Authors:  R S Ochs; R A Harris
Journal:  Lipids       Date:  1980-07       Impact factor: 1.880

9.  Hyperglucagonemia in cirrhosis: altered secretion and sensitivity to glucagon.

Authors:  R S Sherwin; M Fisher; J Bessoff; N Snyder; R Hendler; H O Conn; P Felig
Journal:  Gastroenterology       Date:  1978-06       Impact factor: 22.682

10.  Ketoacidosis in pancreatectomized man.

Authors:  A J Barnes; S R Bloom; K Goerge; G M Alberti; P Smythe; F P Alford; D J Chisholm
Journal:  N Engl J Med       Date:  1977-06-02       Impact factor: 91.245

View more
  7 in total

1.  Hyperalaninaemia is an early feature of diabetes secondary to total pancreatectomy.

Authors:  S Del Prato; S Vigili de Kreutzenberg; R Trevisan; E Duner; A Avogaro; R Nosadini; U Baccaglini; C Tremolada; A Tiengo
Journal:  Diabetologia       Date:  1985-05       Impact factor: 10.122

Review 2.  Diabetes after pancreatic surgery: novel issues.

Authors:  Marina Scavini; Erica Dugnani; Valentina Pasquale; Daniela Liberati; Francesca Aleotti; Gaetano Di Terlizzi; Giovanna Petrella; Gianpaolo Balzano; Lorenzo Piemonti
Journal:  Curr Diab Rep       Date:  2015-04       Impact factor: 4.810

Review 3.  Nutritional status and nutritional support before and after pancreatectomy for pancreatic cancer and chronic pancreatitis.

Authors:  Vasiliki Th Karagianni; Apostolos E Papalois; John K Triantafillidis
Journal:  Indian J Surg Oncol       Date:  2012-10-30

4.  Hyperglucagonemia and insulin-mediated glucose metabolism.

Authors:  S Del Prato; P Castellino; D C Simonson; R A DeFronzo
Journal:  J Clin Invest       Date:  1987-02       Impact factor: 14.808

5.  Idiopathic reactive hypoglycemia: a role for glucagon?

Authors:  F Leonetti; L Morviducci; A Giaccari; P Sbraccia; S Caiola; D Zorretta; O Lostia; G Tamburrano
Journal:  J Endocrinol Invest       Date:  1992-04       Impact factor: 4.256

6.  Metabolic consequences of (regional) total pancreatectomy.

Authors:  C M Dresler; J G Fortner; K McDermott; D R Bajorunas
Journal:  Ann Surg       Date:  1991-08       Impact factor: 12.969

7.  Glucagon as a critical factor in the pathology of diabetes.

Authors:  Dale S Edgerton; Alan D Cherrington
Journal:  Diabetes       Date:  2011-02       Impact factor: 9.461

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.